IP Library Granted Patent US 12,398,360
Granted Patent B2
US 12,398,360 · App. 17/059,769 · Granted Aug 26, 2025

Cell engineering platform

Inventor: Michael Maguire (Dublin, IE)
Assignee: AVECTAS LIMITED
C12M35/08C12M3/00C12M25/02C12N5/0068C12N5/0634C12N15/87
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,398,360
App. No.
17/059,769
Granted
Aug 26, 2025
Kind
B2
Abstract

The current subject matter provides a cell engineering platform of a diagnostic and clinical use scale for vector-free and/or viral delivery of payload/cargo compounds and compositions into non-adherent cells. The platform achieves delivery to a large number of cells quickly in a closed system. Related apparatus, systems, techniques, articles and compositions are also described.

Claims (55)

1. A system comprising:

a housing configured to receive a filter plate comprising a well;

a differential pressure applicator configured to apply a differential pressure to the well;

a delivery solution applicator configured to deliver atomized delivery solution to the well;

a stop solution applicator configured to deliver a stop solution to the well; and

a culture medium applicator configured to deliver a culture medium to the well.

2. The system of claim 1 , wherein the housing comprises:

a chamber;

a lid disposed at a first end of the chamber; and

a base disposed at a second end of the chamber,

wherein the filter plate is disposed within the chamber.

3. The system of claim 2 , wherein the differential pressure applicator is connected to the lid of the housing and includes a shower head, which includes a plurality of apertures at an end portion thereof.

4. The system of claim 2 , wherein the stop solution applicator delivers the stop solution to the well through a septum provided in the lid of the housing.

5. The system of claim 2 , wherein the culture medium applicator delivers the culture medium to the well through a septum provided in the lid of the housing or through a port of the chamber.

6. The system of claim 1 , wherein the housing is configured to tilt the filter plate.

7. The system of claim 1 , wherein the delivery solution applicator includes a robotic arm and spray head, the robotic arm magnetically coupled to the spray head.

8. The system of claim 7 , further comprising a soft elastomeric barrier enclosing the filter plate and spray head, wherein the soft elastomeric barrier separates the robotic arm and the spray head.

9. The system of claim 7 , wherein the robotic arm is configured to carry the spray head to a plurality of locations on the filter plate.

10. The system of claim 1 , wherein the stop solution applicator and the culture medium applicator are formed integral within the housing as ports, and wherein the housing forms a vessel.

11. The system of claim 10 , wherein the vessel includes a waste media outlet for collecting waste media.

12. The system of claim 1 , further comprising a soft elastomeric barrier enclosing the filter plate and delivery solution applicator within the housing, the soft elastomeric barrier and the housing forming a bioreactor.

13. The system of claim 1 , wherein the housing includes a filter plate base configured to tilt, rotate, and/or vibrate the filter plate.

14. The system of claim 1 , wherein the delivery solution applicator includes a robotic arm and spray head, and the spray head is a single-use cartridge.

15. The system of claim 1 , wherein the filter plate is sized to hold greater than 1×10 7 T cells.

16. The system of claim 1 , wherein the system is configured to automatically:

provide to the filter plate cells in media;

remove culture media to form a cellular monolayer on top of the filter plate;

apply an atomized delivery solution to the cellular monolayer;

incubate the cells,

apply a stop solution to the incubated cellular monolayer; and

provide new media to the cellular monolayer.

17. The system of claim 16 , wherein the system is configured to automatically tilt, vibrate, and/or rotate the filter plate to re-suspend the cells in the new media.

18. The system of claim 16 , wherein the system is configured to repeat the application of the atomized delivery solution, the incubation, and the application of the stop solution.

19. The system of claim 1 , wherein the delivery solution applicator includes a nebulizer.

20. The system of claim 19 , wherein the delivery solution applicator further includes a mass flow controller or a volumetric flow controller to regulate a gas flow to operate the nebulizer.

21. The system of claim 1 , wherein the delivery solution applicator is configured to deliver 10-300 micro liters of the delivery solution per actuation.

22. The system of claim 1 , further comprising a temperature control system configured to control a temperature of the delivery solution and/or of the plate comprising the well.

23. The system of claim 1 , wherein the delivery solution includes an aqueous solution, the aqueous solution including the payload and an alcohol at greater than 2 percent (v/v) concentration.

24. The system of claim 23 , wherein said alcohol comprises ethanol.

25. The system of claim 23 , wherein said aqueous solution comprises greater than 5% ethanol.

26. The system of claim 23 , wherein said aqueous solution comprises between 5-30% ethanol.

27. The system of claim 23 , wherein said aqueous solution comprises 12% or 25% ethanol.

28. The system of claim 23 , wherein said aqueous solution comprises between 12.5-500 mM KCl.

29. The system of claim 23 , wherein said aqueous solution comprises 106 mM KCl.

30. The system of claim 1 , further comprising:

the filter plate, wherein the well is configured to contain a population of non-adherent cells.

31. The system of claim 30 , wherein said non-adherent cell comprises a peripheral blood mononuclear cell.

32. The system of claim 30 , wherein said non-adherent cell comprises an immune cell.

33. The system of claim 30 , wherein said non-adherent cell comprises a T lymphocyte.

34. The system of claim 23 , wherein said payload comprises a messenger ribonucleic acid (mRNA).

35. The system of claim 34 , wherein said mRNA encodes a gene-editing composition.

36. The system of claim 35 , wherein said gene editing composition reduces the expression of PD-1.

37. The system of claim 34 , wherein said mRNA encodes a chimeric antigen receptor.

38. The system of claim 1 for use to deliver a cargo compound or composition to a mammalian cell.

39. The system of claim 30 , wherein said population of non-adherent cells comprises a monolayer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2023
From: MAGUIRE, MICHAEL
To: AVECTAS LIMITED
Reel/Frame 064855/0769 →
Continuity (2)
Provisional Application 62679715 · Jun 1, 2018
Related Publication 20210261901A1 · Aug 26, 2021
References Cited (48)
US 5411208A · Burgener · 1995 [cited by applicant]
US 5534423A · Palsson · 1996 [cited by examiner]
US 5654185A · Palsson · 1997 [cited by examiner]
US 5877023A · Sautter · 1999 [cited by examiner]
US 5914245A · Bylina et al. · 1999 [cited by applicant]
US 5922687A · Mann · 1999 [cited by examiner]
US 6093557A · Pui · 2000 [cited by examiner]
US 6472163B1 · Coleman et al. · 2002 [cited by applicant]
US 6634572B1 · Burgener · 2003 [cited by applicant]
US 7667004B2 · Zhong et al. · 2010 [cited by applicant]
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 8779382B1 · Tsai · 2014 [cited by examiner]
US 8932814B2 · Cong et al. · 2015 [cited by applicant]
US 9023649B2 · Mali et al. · 2015 [cited by applicant]
US 9074199B1 · Chavez et al. · 2015 [cited by applicant]
US 10214750B2 · Borenstein · 2019 [cited by examiner]
US 10562048B2 · Chen · 2020 [cited by examiner]
US 20020146825A1 · Uhler · 2002 [cited by examiner]
US 20030092181A1 · Webb · 2003 [cited by examiner]
US 20050170510A1 · Huang · 2005 [cited by examiner]
US 20080248575A1 · Lee · 2008 [cited by examiner]
US 20190292510A1 · Tandon · 2019 [cited by examiner]
US 20210284945A1 · Maguire · 2021 [cited by applicant]
US 20220233716A1 · Maguire et al. · 2022 [cited by applicant]
CN 107206015A · 2017 [cited by applicant]
WO 2008074980A1 · 2008 [cited by applicant]
WO 2015071474A3 · 2015 [cited by applicant]
WO 2018115973A2 · 2016 [cited by applicant]
WO 2017115128A2 · 2017 [cited by applicant]
WO 2018074980A1 · 2018 [cited by applicant]
WO 2016065341A1 · 2018 [cited by applicant]
WO 2019229722A1 · 2019 [cited by applicant]
PCT Search Report and Written Opinion issued in connection with corresponding PCT Application No. PCT/IB2019/054555 on Dec. 5, 2019. [cited by applicant]
Besser et al., ( 2009) “Modifying Interleukin-2 Concentrations During Culture Improves Function of T Cells for Adoptive Immunotherapy”, Cytotherapy, 11(2):206-217. [cited by applicant]
Brocard et al., (Dec. 2006) “Peroxisome Targeting Signal 1: Is it Really a Simple Tripeptide?”, Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1763(12):1565-1573. [cited by applicant]
Cho et al., (Mar. 2013) “Targeted Genome Engineering in Human Cells with the Cas9 RNA-Guided Endonuclease”, Nature Biotechnology, 31(3):230-232. [cited by applicant]
Dingwall et al., (Dec. 1991) “Nuclear Targeting Sequences—A Consensus?”, Trends in Biochemical Sciences, 16(12):478-481. [cited by applicant]
Jinek et al., (Aug. 17, 2012) “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity”, Science, 337(6096):816-821. [cited by applicant]
Kalderon et al., (Dec. 1984) “A Short Amino Acid Sequence Able to Specify Nuclear Location”, Cell, 39( Pt 2):499-509. [cited by applicant]
Makkerh et al., (Aug. 1996) “Comparative Mutagenesis of Nuclear Localization Signals Reveals the Importance of Neutral and Acidic Amino Acids”, Current Biology, 6(8):1025-1027. [cited by applicant]
Nakamura et al., (2000) “Codon Usage Tabulated from International DNA Sequence Database: Status for the Year 2000”, Nucleic Acid Research, 28(1):292. [cited by applicant]
Omura, Tsuneo, (1998) “Mitochondria-Targeting Sequence, a Multi-Role Sorting Sequence Recognized at All Steps of Protein Import into Mitochondria”, The Journal of Biochemistry, 123(6):1010-1016. [cited by applicant]
Park et al., (Aug. 2015) “Engineering Mesenchymal Stem Cells for Regenerative Medicine and Drug Delivery”, Methods, 84:3-16. [cited by applicant]
Ran et al., (Nov. 2013) “Genome engineering using the CRISPR-Cas9 system”, Nature Protocols, 8 (11):2281-2308. [cited by applicant]
Rapaport, Doron, (Nov. 2003) “Finding the Right Organelle. Targeting Signals in Mitochondrial Outer-Membrane Proteins”, EMBO Reports, 4(10):948-952. [cited by applicant]
Scott et al., (Aug. 3, 2011) “NoD: A Nucleolar Localization Sequence Detector for Eukaryotic and Viral Proteins”, BMC Bioinformatics, 12:317 (7 pages). [cited by applicant]
Tumeh et al., (Oct. 2010) “The Impact of Ex Vivo Clinical Grade Activation Protocols on Human T cell Phenotype and Function for the Generation of Genetically Modified Cells for Adoptive Cell Transfer Therapy”, Journal o… [cited by applicant]
O'Dea et al., (Mar. 30, 2017) “Vector-Free Intracellular Delivery by Reversible Permeabilization”, PLOS One, 12(3): e0174779 (23 pages). [cited by applicant]